Champions Oncology Inc. (CSBR)
| Bid | 8.24 |
| Market Cap | 125.75M |
| Revenue (ttm) | 59.1M |
| Net Income (ttm) | 6.48M |
| EPS (ttm) | 0.45 |
| PE Ratio (ttm) | 20.22 |
| Forward PE | 44.71 |
| Analyst | Strong Buy |
| Ask | 10.3 |
| Volume | 56,224 |
| Avg. Volume (20D) | 49,748 |
| Open | 9.72 |
| Previous Close | 9.50 |
| Day's Range | 9.05 - 9.70 |
| 52-Week Range | 3.60 - 11.99 |
| Beta | 0.20 |
About CSBR
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune...
Analyst Forecast
According to 1 analyst ratings, the average rating for CSBR stock is "Strong Buy." The 12-month stock price forecast is $12, which is an increase of 31.87% from the latest price.
Stock Forecasts
3 weeks ago · accessnewswire.com
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will ...
